GTCR LLC / Corza Medical
GTCR signs agreement to sell Corza Medical's Biosurgery unit to EQT
Summary: Corza Medical announced on July 7, 2026, that GTCR signed a definitive agreement for Corza Medical to sell its Biosurgery business unit, including the TachoSil product portfolio, to EQT. EQT's own announcement separately supports the buyer, asset, and expected-closing framing for the TachoSil biosurgery transaction.
Why it matters: The update may matter to due-diligence readers as a current portfolio-company reshaping and partial-divestiture signal for a GTCR-backed medical-technology platform; it should not be read as investment advice or as validation of sale proceeds, valuation, financing, regulatory outcomes, product quality, expected returns, or suitability.
Summary
Corza Medical announced on July 7, 2026, that GTCR signed a definitive agreement for Corza Medical to sell its Biosurgery business unit, including the TachoSil product portfolio, to EQT. The Corza source says financial terms were not disclosed and that GTCR will retain ownership of Corza Medical and its Wound Closure, Ophthalmology, and Biomedical Textiles business units.
EQT’s own announcement separately supports the buyer, asset, and expected-closing framing for the TachoSil biosurgery transaction. This draft treats the item as a pending transaction based on transaction-party announcements, not as a completed sale unless a later public source confirms closing.
Why it matters
For due-diligence readers, the useful signal is portfolio-company reshaping at a GTCR-backed medical-technology platform: one business unit is moving to a new buyer while Corza is described as retaining other surgical-technology lines. That may help readers track GTCR platform activity, divestiture sequencing, retained operating focus, and follow-on disclosures about Corza’s remaining businesses.
The signal is bounded. The transaction-party sources can support the definitive-agreement status, asset description, buyer, retained-business framing, and undisclosed financial terms, but they do not establish valuation, financing, sale proceeds, regulatory outcomes, integration plans, product quality, medical outcomes, expected returns, or any allocation decision.
Source notes
- Corza Medical / GTCR transaction-party announcement: https://corza.com/gtcr-announces-divestiture-of-corza-medicals-biosurgery-business-unit-to-eqt/
- EQT buyer announcement: https://eqtgroup.com/news/eqt-to-acquire-the-tachosil-biosurgery-business-from-corza-medical-2026-07-07
- Source posture: primary transaction-party source plus buyer-source support. Attribute the GTCR role, definitive-agreement wording, Corza Medical, Biosurgery unit, TachoSil, undisclosed financial terms, and retained Corza business-unit language to the Corza source; use the EQT source as separate support for EQT’s buyer/asset/expected-close framing.
- Verifier support: source-body checks recovered a Corza page with markers for GTCR, definitive agreement, Corza Medical, Biosurgery, EQT, TachoSil, retain ownership, Wound Closure, Ophthalmology, and Biomedical Textiles. EQT’s page independently supported EQT, TachoSil, biosurgery, Corza Medical, acquire, and expected-to-close language.
- Duplicate posture: verifier scans found no existing local same-event post or draft for Corza Medical / TachoSil / Biosurgery before this draft. Existing GTCR coverage concerns different events.
9AT filing context
For identity and platform background only, public adviser/private-fund-derived context reviewed for this cycle maps GTCR LLC to a Chicago registered adviser with CRD 159545 / SEC file 801-73424, about $48.6 billion in reported ADV AUM, about $48.6 billion in total private-fund gross asset value, 204 employees, and 83 private funds. Public filing-derived context also identifies GTCR as a 13F filer with CIK 1576350.
GTCR’s latest available 13F context reviewed for this cycle was for the period ended 2025-09-30, filed 2025-11-13, with three reported positions and about $905.8 million in total reported value. The positions were Sotera Health, Gogo, and Maravai LifeSciences, with Sotera Health representing the largest reported position by value in that filing.
That filing context is separate from the Corza/TachoSil private transaction. It should not be used to identify a seller fund, infer Corza ownership, estimate sale proceeds, discuss financing or valuation, judge medical-technology exposure, forecast regulatory outcomes, or imply investment merit. The transaction facts in this draft come from the Corza and EQT public announcements.
No Form 5500 context is included because this item concerns a private-equity portfolio-company divestiture rather than a plan-sponsor retirement-plan signal.
What to watch
Watch for a closing announcement from Corza, GTCR, EQT, or other transaction parties; any public disclosure of transaction conditions, regulatory approvals, ownership structure, or financing; and later Corza updates on its retained Wound Closure, Ophthalmology, and Biomedical Textiles businesses. Future coverage should keep product-quality, integration, regulatory, proceeds, valuation, and performance claims tied to fresh public sources rather than deriving them from the announcement or filing background.